At Syngene, we empower biopharmaceutical companies to bring large molecule therapies to life through our state-of-the-art biologics CDMO services across the U.S. and India. With over 30 years of experience, we deliver integrated, expert-driven solutions that accelerate development, ensure compliance, and turn breakthrough ideas into market-ready products.
What We Offer
150+
Gene to GMP in 10 months
25+
20+ mAbs delivered to IND
250+
Regulatory expertise: FDA, EMA, PMDA
50 KL
Titers up to 12g/L using SynWeave™ + N-1 perfusion
2 KL & 4 KL
Up to 50KL GMP capacity
7-12 g/L
50L–4KL single-use bioreactors
>80%
500L microbial fermentors
Why Syngene Biologics
150+
Successful projects
25+
INDs enabled
250+
GMP batches
50 KL
Global GMP* capacity
2 KL & 4 KL
SUBs across the U.S. and India
7-12 g/L
Titer with SynWeave Platform
>80%
Green power
1M
Vials per day
Expertise Across the Spectrum
Our end-to-end services cover every stage of biopharmaceutical development and manufacturing—from cell line and process development to formulation, analytics, and validation. With a seamless, integrated approach, we bring your biologic products to life with speed, precision, and quality.
Regulatory Track Record
FDA, MHRA, and PMDA approvals for our manufacturing sites.
140+ projects across multiple modalities delivered.
Efficiency & Quality
High titers, shorter timelines, no compromise on quality.
Syngene's Integrated Services Across the Drug Lifecycle
Our Offerings Across the Drug Lifecycle
Target ID, Validation and Lead Generation
Lead Optimization and Selection
Cell Line Development and Cell Banking (MCB/WCB)
Process Development, Analytical and Scale-up
GMP Supply (DS /DP) for Early-Phase Clinical Trials
Process Validation and Late-Stage Trials
Product Launch, and Commercial Manufacturing
Hit to Lead
Our Discovery Services provide drug candidates that have been screened and validated through our pre-clinical trials and humanized models
Gene to GMP
Our SynWeave™* high-yielding cell line platform consistently provides 7-12 g/L titers using our process development capabilities in 10 months
Launch Ready
Our USFDA and EMA approved GMP facilities feature single-use bioreactors with capacities of 2,000 L and 4,000 L totaling 50,000 L designed to deliver economies of scale
Early Adopter
We are on the move with next generation technologies that reduce cost ($/g) by 50% using perfusion and continuous purification processing